FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283067220> ?p ?o ?g. }

• W4283067220 endingPage "4593" @default.
• W4283067220 startingPage "4580" @default.
• W4283067220 abstract "Yellow fever (YF) vaccination is known to induce a suboptimal response in patients with autoimmune diseases (AIDs). To date, few studies have focused on the performance of 17DD-YF vaccination in patients with spondyloarthritis (SpA). In general, patients with SpA are young and have less comorbidities than other patients with AIDs, and frequently receive biological disease-modifying antirheumatic drugs (DMARDs) that may impact their response to vaccines. Taking this background information, the present study aimed to investigate whether the use of biological DMARDs, even after planned washout, or disease activity measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), would impact the overall performance of planned 17DD-YF primary vaccination in patients with SpA. For this purpose, 74 subjects were enrolled in a prospective study, including adult patients with SpA (SpA; n = 51) and a healthy control (HC; n = 23) group. Analysis of YF specific neutralizing antibodies test (PRNT), along with YF viremia and the levels of serum chemokines, cytokines, and growth factors were performed at distinct time points (D0, D3, D4, D5, D6, D7, D14, and D28). The BASDAI scores were evaluated at D0 and D180. Data demonstrated that overall, the SpA group presented lower PRNT titers and seropositivity rates as compared to the HC group (GeoMean = 112 vs. 440; 73% vs. 96%, respectively). In SpA subgroup analyses, previous biological DMARDs (BIO-IT) led to a lower PRNT titers (BIO-IT 79, 95% CI [39-150] vs. without biological DMARDs [non-BIO-IT] 159, 95% CI [94-267], p < 0.001). The non-BIO-IT group achieved a response similar to the HC group (81% vs. 96%, p = 0.112), whereas the BIO-IT group had a lower seroconversion rate (64% vs. 96% HC, p = 0.007). The BASDAI was not associated with PRNT levels and did not change after 6 months of follow-up. No differences in YF viremia were observed amongst subgroups. Higher baseline levels of serum biomarkers were observed in the BIO-IT group vs. the non-BIO-IT group, as well as in those with a BASDAI ≥ 4 vs. those with a BASDAI < 4. Increasing levels of several biomarkers were observed in SpA, especially in the BIO-IT and BASDAI ≥ 4 subgroups throughout the timeline kinetics, with impairment/disturbance in the IFN-γ/IL-10 axis around the peak of viremia (D5). Altogether, these findings suggested that the use of biological DMARDs impacts the response to the 17DD-YF vaccine, even after planned washout. Therefore, previous biological DMARD therapy, the inflammatory status prior vaccination, and impairment of the IFN-γ/IL-10 axis at the peak of viremia may determine the immunogenicity of 17DD-YF vaccination in patients with SpA." @default.
• W4283067220 created "2022-06-19" @default.
• W4283067220 creator A5005715947 @default.
• W4283067220 creator A5013539612 @default.
• W4283067220 creator A5015884311 @default.
• W4283067220 creator A5017523406 @default.
• W4283067220 creator A5018625719 @default.
• W4283067220 creator A5019063068 @default.
• W4283067220 creator A5020233707 @default.
• W4283067220 creator A5022976564 @default.
• W4283067220 creator A5025754771 @default.
• W4283067220 creator A5050253137 @default.
• W4283067220 creator A5050470455 @default.
• W4283067220 creator A5051264724 @default.
• W4283067220 creator A5053799940 @default.
• W4283067220 creator A5055017119 @default.
• W4283067220 creator A5056633426 @default.
• W4283067220 creator A5059003875 @default.
• W4283067220 creator A5060422799 @default.
• W4283067220 creator A5061761843 @default.
• W4283067220 creator A5069793092 @default.
• W4283067220 creator A5070158457 @default.
• W4283067220 creator A5075854813 @default.
• W4283067220 creator A5078880226 @default.
• W4283067220 creator A5079783990 @default.
• W4283067220 creator A5091320118 @default.
• W4283067220 date "2022-07-01" @default.
• W4283067220 modified "2023-10-16" @default.
• W4283067220 title "Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis" @default.
• W4283067220 cites W1967538787 @default.
• W4283067220 cites W1980115073 @default.
• W4283067220 cites W1994415441 @default.
• W4283067220 cites W2005333995 @default.
• W4283067220 cites W2010436800 @default.
• W4283067220 cites W2016480047 @default.
• W4283067220 cites W2083346028 @default.
• W4283067220 cites W2083347487 @default.
• W4283067220 cites W2095406037 @default.
• W4283067220 cites W2107231684 @default.
• W4283067220 cites W2109172918 @default.
• W4283067220 cites W2120296135 @default.
• W4283067220 cites W2155083074 @default.
• W4283067220 cites W2155539357 @default.
• W4283067220 cites W2299402461 @default.
• W4283067220 cites W2516535731 @default.
• W4283067220 cites W2529373723 @default.
• W4283067220 cites W2594066459 @default.
• W4283067220 cites W2797474345 @default.
• W4283067220 cites W2806145862 @default.
• W4283067220 cites W2808733288 @default.
• W4283067220 cites W2905444998 @default.
• W4283067220 cites W2944250071 @default.
• W4283067220 cites W2953889774 @default.
• W4283067220 cites W2972635716 @default.
• W4283067220 cites W3043370845 @default.
• W4283067220 cites W3120923922 @default.
• W4283067220 cites W3192305430 @default.
• W4283067220 cites W4240905451 @default.
• W4283067220 cites W4255504044 @default.
• W4283067220 doi "https://doi.org/10.1016/j.vaccine.2022.05.071" @default.
• W4283067220 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35728990" @default.
• W4283067220 hasPublicationYear "2022" @default.
• W4283067220 type Work @default.
• W4283067220 citedByCount "1" @default.
• W4283067220 countsByYear W42830672202023 @default.
• W4283067220 crossrefType "journal-article" @default.
• W4283067220 hasAuthorship W4283067220A5005715947 @default.
• W4283067220 hasAuthorship W4283067220A5013539612 @default.
• W4283067220 hasAuthorship W4283067220A5015884311 @default.
• W4283067220 hasAuthorship W4283067220A5017523406 @default.
• W4283067220 hasAuthorship W4283067220A5018625719 @default.
• W4283067220 hasAuthorship W4283067220A5019063068 @default.
• W4283067220 hasAuthorship W4283067220A5020233707 @default.
• W4283067220 hasAuthorship W4283067220A5022976564 @default.
• W4283067220 hasAuthorship W4283067220A5025754771 @default.
• W4283067220 hasAuthorship W4283067220A5050253137 @default.
• W4283067220 hasAuthorship W4283067220A5050470455 @default.
• W4283067220 hasAuthorship W4283067220A5051264724 @default.
• W4283067220 hasAuthorship W4283067220A5053799940 @default.
• W4283067220 hasAuthorship W4283067220A5055017119 @default.
• W4283067220 hasAuthorship W4283067220A5056633426 @default.
• W4283067220 hasAuthorship W4283067220A5059003875 @default.
• W4283067220 hasAuthorship W4283067220A5060422799 @default.
• W4283067220 hasAuthorship W4283067220A5061761843 @default.
• W4283067220 hasAuthorship W4283067220A5069793092 @default.
• W4283067220 hasAuthorship W4283067220A5070158457 @default.
• W4283067220 hasAuthorship W4283067220A5075854813 @default.
• W4283067220 hasAuthorship W4283067220A5078880226 @default.
• W4283067220 hasAuthorship W4283067220A5079783990 @default.
• W4283067220 hasAuthorship W4283067220A5091320118 @default.
• W4283067220 hasConcept C126322002 @default.
• W4283067220 hasConcept C159654299 @default.
• W4283067220 hasConcept C197934379 @default.
• W4283067220 hasConcept C203014093 @default.
• W4283067220 hasConcept C22070199 @default.
• W4283067220 hasConcept C2776185481 @default.
• W4283067220 hasConcept C2776260265 @default.
• W4283067220 hasConcept C2777178219 @default.

• next